Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem Oncology will host an investor conference call on June 23, 2026, to present updated preliminary clinical data for its lead asset VS-7375. The data covers the Phase 1/2 TARGET-D 101 trial, including safety, tolerability, and pharmacokinetic findings across pancreatic, colorectal, and non-small cell lung cancers.
Key figures
- Drug Name
- VS-7375
- Phase Of Trial
- Phase 1/2
- Event date
- June 23, 2026
- Trial name
- TARGET-D 101
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.